# 02_KNOWLEDGE_PASSPORT --- PP-0179 Lauren Classification

## Identity

-   **KP ID:** KP-PP-0179
-   **PP ID:** PP-0179
-   **Title:** Lauren Classification
-   **Version:** 1.0.0
-   **Status:** GOLD --- READY FOR INTEGRATION
-   **Last Updated:** 2026-08-09

## Knowledge Classification

-   **Clinical Domain:** Diagnosis / Pathology / Histologic
    Classification
-   **Primary Knowledge Type:** Patient-facing clinical education
-   **Secondary Knowledge Types:** Histologic classification, pathology
    interpretation context, clinical-pathologic integration
-   **Clinical Complexity:** Intermediate
-   **Educational Level:** Foundational-to-intermediate
-   **Atomic Clinical Question:** What is Lauren Classification, what do
    its intestinal, diffuse and mixed categories mean, and how should
    the classification be understood within the overall gastric cancer
    pathology picture?
-   **Primary Runtime Intent:** Explain Lauren Classification and
    prevent conflation with stage, grade, molecular classification or
    treatment.
-   **Primary Clinical Dependency:** Histopathologic examination of
    gastric adenocarcinoma tissue.
-   **Primary Downstream Dependencies:** WHO classification, molecular
    classification, biomarker testing and clinical integration.

## Patient Journey Classification

-   **Journey Stage:** Diagnosis → Pathology characterization →
    Molecular/biomarker characterization
-   **Primary Patient Question:** "My pathology says intestinal, diffuse
    or mixed type. What does that mean?"
-   **Secondary Patient Questions:**
    -   "Is diffuse type the same as advanced cancer?"
    -   "Is intestinal type better?"
    -   "Why can the classification change after surgery?"
    -   "How is Lauren different from stage or grade?"
    -   "Does Lauren type determine treatment?"

## Intended Runtime Usage

This package is intended to:

1.  Explain the Lauren framework in patient-friendly language.
2.  Explain intestinal, diffuse and mixed categories.
3.  Connect microscopic morphology to the classification without
    duplicating PP-0178.
4.  Explain why specimen limitations and heterogeneity matter.
5.  Prevent confusion between Lauren type, grade, differentiation,
    stage, WHO classification and molecular classification.
6.  Introduce high-level biomarker associations without replacing
    dedicated testing packages.
7.  Prevent independent prognostic or treatment overinterpretation.

## Retrieval / Runtime Relevance

### High-Priority Retrieval Concepts

-   Lauren Classification
-   gastric adenocarcinoma intestinal type
-   gastric adenocarcinoma diffuse type
-   mixed gastric adenocarcinoma
-   signet-ring cell gastric cancer
-   poorly cohesive gastric cancer
-   histologic subtype gastric cancer
-   Lauren vs WHO
-   Lauren vs TNM
-   Lauren vs molecular classification
-   Lauren and HER2
-   Lauren and CLDN18.2
-   gastric pathology classification

### Query Expansion Terms

-   intestinal diffuse mixed gastric adenocarcinoma
-   Lauren histologic classification
-   gastric cancer histologic subtype
-   diffuse type signet ring gastric cancer
-   intestinal type gastric adenocarcinoma
-   mixed intestinal diffuse gastric cancer
-   gastric cancer pathology classification
-   Lauren classification prognosis limitation
-   Lauren classification treatment relevance

## Knowledge Graph

### Prerequisites

-   PP-0175 --- Gastric Cancer Diagnostic Work-up
-   PP-0176 --- Endoscopic Diagnosis of Gastric Cancer
-   PP-0177 --- Endoscopic Biopsy Strategy
-   PP-0178 --- Histopathologic Classification

### Related

-   PP-0033 --- Understanding Your Pathology Report
-   PP-0034 --- How to Read Your Pathology Report
-   PP-0035 --- Histologic Types of Gastric Cancer
-   PP-0038 --- Tumor Grade
-   PP-0039 --- Histologic Differentiation
-   PP-0168 --- EBV-associated Gastric Cancer + EBV Testing
-   Hereditary Diffuse Gastric Cancer

### Downstream

-   PP-0180 --- Gastric Cancer Molecular Classification
-   PP-0181--PP-0187 --- Biomarker/NGS Testing
-   PP-0188 --- Molecular Subtypes of Gastric Cancer
-   PP-0189 --- Genomic Test Results / How to Read a Molecular Report
-   PP-0190--PP-0191 --- Biomarker-guided Treatment

## Clinical Scope

### Core Knowledge Ownership

PP-0179 owns the Lauren Classification layer between broad
histopathologic characterization and downstream molecular/biomarker
characterization.

It owns:

-   definition and purpose;
-   intestinal, diffuse and mixed categories;
-   classification logic;
-   relevant morphology;
-   specimen and heterogeneity limitations;
-   relationship with grade, differentiation, stage, WHO and molecular
    classification;
-   selected biomarker context;
-   interpretation limits.

### Supporting Knowledge

-   linitis plastica as diffuse-type context;
-   signet-ring/poorly cohesive context;
-   pathology review;
-   biopsy versus resection;
-   selected biomarker associations;
-   hereditary context at a cross-reference level;
-   patient-facing terminology.

### Explicit Exclusions

The package does not own:

-   detailed histopathology;
-   endoscopy;
-   biopsy technique;
-   WHO taxonomy;
-   grading methodology;
-   staging;
-   biomarker testing;
-   molecular classification;
-   NGS;
-   genomic interpretation;
-   hereditary testing;
-   individualized prognosis;
-   treatment algorithms.

## Authoritative Sources

### Primary Clinical Sources

1.  NCCN Gastric Cancer Version 2.2026.
2.  NCI Gastric Cancer / Stomach Cancer PDQ materials.
3.  NCI Hereditary Diffuse Gastric Cancer PDQ where directly relevant to
    diffuse/signet-ring morphology.

### Supporting Sources

-   ACS Stomach Cancer materials.
-   ESMO--ASCO Recommendations for a Global Curriculum in Medical
    Oncology, 2023.
-   PP Registry.
-   Locked Gold Population Package Specification v1.0.
-   CORE_WORKING_RULES v1.6.
-   Approved Gold package and Discussion Batch references.

## Evidence Classification

  -----------------------------------------------------------------------
  Knowledge Area          Evidence Class          Primary Support
  ----------------------- ----------------------- -----------------------
  Lauren                  Established             NCCN, NCI
  intestinal/diffuse                              
  framework                                       

  Mixed                   Established             NCI
  intestinal/diffuse                              
  morphology                                      

  Intestinal morphology   Established             NCCN, NCI

  Diffuse/poorly cohesive Established             NCCN, NCI
  morphology                                      

  Signet-ring morphology  Established             NCCN, NCI HDGC PDQ

  Specimen limitations    Established             NCCN, NCI

  Lauren vs grade         Established conceptual  NCCN + Registry
                          distinction             

  Lauren vs TNM           Established conceptual  Registry + NCCN
                          distinction             

  Lauren vs WHO           Established             Registry
                          architecture            
                          distinction             

  Lauren vs molecular     Established             NCCN + Registry
  classification          complementary framework 

  Histologic subtype and  Guideline-supported     NCCN
  HER2 association        association             

  Independent prognosis   Not supported as        Registry boundary
  from Lauren alone       standalone rule         

  Independent treatment   Not supported           Registry boundary
  selection from Lauren                           
  alone                                           
  -----------------------------------------------------------------------

## Governance Metadata

-   **Execution Rule:** User-controlled PP sequence.
-   **Source Rule:** Source-first.
-   **Clinical Content Rule:** Source-grounded; unsupported details are
    not invented.
-   **Artifact Rule:** Four governed artifacts.
-   **Depth Rule:** Absolute full-depth compliance; equal to approved
    Gold reference depth is the minimum; deeper is permitted when
    justified.
-   **Boundary Rule:** One clean four-part Boundary in final production
    response.
-   **QA Rule:** Four-layer QA.
-   **Repository Readiness:** Ready for integration after final QA.

## Version Control

-   **Semantic Version:** 1.0.0
-   **Change Type:** Initial Gold production from locked Decision Batch.
-   **Supersedes:** None within this PP.
-   **Source Version Context:** NCCN Gastric Cancer v2.2026; current NCI
    PDQ materials; project governance frozen as supplied.

## Change History

  -----------------------------------------------------------------------
  Version                 Date                    Change
  ----------------------- ----------------------- -----------------------
  1.0.0                   2026-08-09              Initial Gold Population
                                                  Package generated after
                                                  PP-0179 approval/lock.

  -----------------------------------------------------------------------

## Final Status

**GOLD --- READY FOR INTEGRATION**
